Floatz logo

INSULIN GLARGINE (SANOFI)

Non-alcoholic Fatty Liver Disease

Fudan Universityprotein_peptidePhase 4 / ApprovedDormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

14 Active assets in the Non-alcoholic Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Sitagliptin
University Health Network, Toronto
Phase 4BB
LOBEGLITAZONE
Yonsei University
Phase 4B
1,25-dihydroxyvitamin d
University Hospital Rijeka
Phase 4B
Actos
Zagazig University
Phase 4B
Ornithine Aspartate
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4B

View all 47 →

Same molecule, other indications

INSULIN GLARGINE (SANOFI) is also rated in:

Diabetes Mellitus, Type 2Dormant
BB
Indicative ·
66 / 100
View asset →
HyperglycemiaDormant
B
Indicative ·
63 / 100
View asset →
Cardiovascular DiseasesDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →